REG - BkofA Merrill Lynch Allergan PLC - Form 38.5 (b) - Allergan Plc

AbbvieAnnouncement

11/05/2020 12:20

RNS Number : 4951M
  
Bank of America Merrill Lynch
  
11 May 2020
  
 


FORM 38.5(b)
 
IRISH TAKEOVER PANEL



DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997,

TAKEOVER RULES, 2013



DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT

RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNIZED INTERMEDIARY

STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY 
 




1.


KEY INFORMATION










Name of exempt principal trader 






Bank of America, N.A., Proprietary







Company dealt in 






Allergan PLC







Class of relevant security to which the

dealings being disclosed relate(Note 1) 






Common - IE00BY9D5467







Date of dealing 






08/05/2020



 




2.


INTERESTS AND SHORT POSITIONS









(a)


Interests and short positions (following dealing) in the class of relevant security

dealt in (Note 2) 







Class of relevant security: Common


IE00BY9D5467








Long


Short




Number


%


Number


%







(1) 


Relevant securities 






3,979,185


1.209% 


335,008


0.102 % 







(2) 


Derivatives (other than options): 






1,310,928


0.398% 


4,960,456


1.507% 







(3) 


Options and agreements to purchase/sell: 






0


0% 


0


0% 




Total


5,290,113


1.607% 


5,295,464


1.609% 



 




(b)


Interests and short positions in relevant securities of the company, other than the

class dealt in (Note 2) 








Class of relevant security: 












Long


Short




Number


%


Number


%







(1) 


Relevant securities 






0 


0% 


0 


0% 







(2) 


Derivatives (other than options): 






0 


0% 


0 


0% 







(3) 


Options and agreements to purchase/sell: 






0 


0% 


0 


0% 




Total


0 


0% 


0 


0% 








3.


DEALINGS (Note 3)








(a)


Purchases and sales







Purchase/sale


Number of relevant securities


Price per unit (Note 4)




Purchase


75


192.52 USD




Purchase


37


192.53 USD




Purchase


69


192.61 USD




Purchase


11


192.64 USD




Purchase


52


192.8 USD




Purchase


56


192.85 USD




Purchase


43


192.86 USD




Purchase


109


192.88 USD




Purchase


100


192.92 USD




Purchase


42


192.93 USD




Purchase


101


192.94 USD




Purchase


105


192.95 USD




Purchase


214


192.96 USD




Purchase


181


192.97 USD




Purchase


293


192.98 USD




Purchase


92


192.99 USD




Purchase


44,308


193.02 USD




Purchase


53


193.03 USD




Purchase


344


193.04 USD




Purchase


166


193.07 USD




Purchase


100


193.08 USD




Purchase


248


193.09 USD




Purchase


100


193.1 USD




Purchase


184


193.11 USD




Purchase


351


193.15 USD




Purchase


100


193.16 USD



 



Purchase/sale


Number of relevant securities


Price per unit (Note 4)




Sale


11


192.64 USD




Sale


45


192.99 USD




Sale


1,311,553


193.02 USD



 




(b)


Derivatives transactions (other than options transactions) 








Product name,

e.g. CFD 


Nature of transaction

(Note 5)


Number of relevant securities
(Note 6)


Price per unit

(Note 4)




Swaps


Opening a Long Position


42,000


192.99 USD




Swaps


Closing a Long Position


36,000


192.99 USD




Swaps


Reducing a Long Position


26,804


192.99 USD




Swaps


Reducing a Long Position


35,000


192.99 USD




Swaps


Reducing a Short Position


97,804


192.99 USD




Swaps


Closing a Short Position


1,155,117


193.02 USD




Swaps


Reducing a Short Position


109,750


193.02 USD




Swaps


Closing a Long Position


42,000


192.99 USD




Swaps


Increasing a Long Position


7,630


193.02 USD



 




(c)


Options transactions in respect of existing relevant securities 








(i)


Writing, selling, purchasing or varying







Product name, e.g. call option


Writing, selling, purchasing, varying etc.


Number of securities to which the option relates (Note 7)


Exercise price


Type, e.g. American, European etc


Expiry date


Option money paid/ received per unit (Note 4)




N/A


N/A


N/A


N/A


N/A


N/A


N/A



 




(ii)


Exercising








Product name,

e.g. call option 


Number of securities


Exercise price per

unit (Note 4)




N/A


N/A


N/A



 




(d)


Other dealings (including transactions in respect of new securities) (Note 3) 








Nature or transaction
(Note 7)


Details


Price per unit

(if applicable) (Note 4)




N/A


N/A


N/A



 




4.


OTHER INFORMATION




 

Agreements, arrangements or understandings relating to options or derivatives 

 



Full details of any agreement, arrangement or understanding between the person

disclosing and any other person relating to the voting rights of any relevant

securities under any option referred to on this form or relating to the voting rights

or future acquisition or disposal of any relevant securities to which any derivative

referred to on this form is referenced. If none, this should be stated. 




None 



 




Is a Supplemental Form 38.5(b) attached? (Note 8)


No




 



Date of disclosure


11/05/2020




Contact name


Tolu Tade




Telephone number


+44207 996 3410




Name of offeree/offeror with which connected 


AbbVie Inc




Nature of connection (Note 9)


Advisor to - AbbVie Inc



 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
ISEMZGMKGMKGGZM